The Cav1.2 channel is a member of the high voltage activated class of Ca2+ channels known as the L-type Ca2+ channel. Cav1.2 is abundantly present in cardiac muscle where it mediates excitation-contraction coupling, in conjunction with other cardiac ion channels (eg. hERG, Nav1.5, ...).

In the overall cardiac integrated risk assessment for drug candidates, screening for direct activity on Cav1.2 channels is a critical step, which may be efficiently addressed by coupling the voltage clamping technology with a high performance stable cell line.

In this context, our team developed a HEK293 cell line - hCav1.2 HEK293 - stably and homogeneously expressing the human L-type cardiac Ca2+ channel Alpha1C subunit, together with Beta2a and Alpha2Delta subunits.